Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2026-06-26 16:15:07 ET · period of report 2026-06-25 · accession 0001193125-26-285505 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-26 16:15 | 2026-06-25 | DYN | Lucera Erick | CFO | S - Sale | $20.37 | -2,362 | 121.6K | -2% | -$48.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-25 | S | D | 2,362 | $20.37 | 121,563 | D | — | — | (F1) Represents shares sold to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.33 to $20.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. (F3) Includes 110,513 unvested RSUs. |